GSK plc (LON:GSK – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Friday. The stock traded as low as GBX 18.50 and last traded at GBX 1,852.50, with a volume of 199,092,344 shares. The stock had previously closed at GBX 1,827.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the stock. Royal Bank Of Canada started coverage on shares of GSK in a research report on Tuesday, September 8th. They set a “sector perform” rating and a GBX 1,975 target price on the stock. Deutsche Bank reissued a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Tuesday, November 10th. Berenberg Bank reissued a “buy” rating and issued a GBX 2,200 price target on shares of GSK in a report on Tuesday, November 3rd. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a research report on Tuesday, October 20th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, GSK presently has a consensus rating of “Hold” and a consensus price target of GBX 2,145.
GSK Trading Up 0.8%
GSK (LON:GSK – Get Free Report) last issued its earnings results on Wednesday, October 28th. The company reported GBX 54.60 EPS for the quarter. The firm had revenue of GBX 888.70 billion during the quarter. GSK had a return on equity of 24.64% and a net margin of 12.97%. Analysts anticipate that GSK plc will post 175.98 earnings per share for the current year.
Insider Activity at GSK
In related news, insider Anne Beal purchased 637 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were acquired at an average price of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds acquired 1,500 shares of the business’s stock in a transaction on Friday, September 18th. The shares were bought at an average cost of GBX 1,881 per share, with a total value of £28,215. Insiders have purchased a total of 2,151 shares of company stock valued at $6,021,921 in the last 90 days. 0.20% of the stock is owned by corporate insiders.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
See Also
- Five stocks we like better than GSK
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
